Repare Therapeutics Shareholders Approve Acquisition by Xeno Acquisition Corp.
RPTX has more than doubled off its 52-week low of $0.89.
Summary
Repare Therapeutics Inc. shareholders have overwhelmingly approved the acquisition of the company by Xeno Acquisition Corp., marking a definitive step towards the company's exit from independent public trading.
Key Events · M&A and Partnerships · RPTX
-
Acquisition Approved by Shareholders
Shareholders approved the acquisition by Xeno Acquisition Corp. with 99.76% of votes cast, including votes excluding minority security holders.
-
Executive Compensation Approved
An advisory, non-binding resolution to approve executive compensation related to the arrangement was passed with 99.34% of votes.
-
Contingent Liquidation Resolutions Approved
Shareholders also approved resolutions for voluntary liquidation and dissolution, and the appointment of a liquidator, to be enacted only if the acquisition is terminated.
-
Next Steps Towards Closing
The Superior Court of Québec hearing for final approval is scheduled for January 23, 2026, with the completion of the arrangement expected around January 28, 2026.
Analysis · RPTX · Life Sciences
Repare Therapeutics Inc. shareholders have overwhelmingly approved the acquisition of the company by Xeno Acquisition Corp. via a statutory plan of arrangement. This approval is a critical step towards the company's exit from independent public trading, providing a definitive outcome for investors. The high approval rate, including the exclusion of minority security holders, indicates strong shareholder confidence in the transaction. The acquisition is now subject to final court approval, with closing anticipated by late January 2026.
At the time of this filing, RPTX was trading at $2.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.2M. The 52-week trading range was $0.89 to $2.66. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.